Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Nadia Waheed sold 3,510 shares of the firm's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $7.74, for a total value of $27,167.40. Following the transaction, the insider owned 314,907 shares in the company, valued at approximately $2,437,380.18. This trade represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Nadia Waheed also recently made the following trade(s):
- On Thursday, February 12th, Nadia Waheed sold 7,863 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.04, for a total transaction of $71,081.52.
Ocular Therapeutix Stock Performance
Shares of OCUL stock opened at $8.95 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The firm has a 50-day moving average of $10.53 and a 200-day moving average of $11.62. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44. The company has a market cap of $1.95 billion, a P/E ratio of -6.22 and a beta of 0.90.
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business had revenue of $13.25 million for the quarter, compared to analysts' expectations of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The firm's revenue for the quarter was down 22.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.29) earnings per share. Equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.
Trending Headlines about Ocular Therapeutix
Here are the key news stories impacting Ocular Therapeutix this week:
- Positive Sentiment: Director Richard L. Lindstrom purchased 60,229 shares at an average $7.66 (32% increase in his stake), signaling insider confidence and providing direct demand support for the stock. SEC Filing - Lindstrom Form 4
- Positive Sentiment: Ocular Therapeutix will present detailed SOL‑1 data at the 49th Macula Society meeting and host an investor webcast to discuss the presentations — an event that could materially move the stock if data readouts are favorable or provide clearer commercial/clinical outlooks. Ocular Therapeutix to Present SOL‑1 Data
- Neutral Sentiment: Ongoing coverage: a Yahoo Finance piece reassesses OCUL after a sharp pullback, offering analysis on valuation that could influence investor sentiment but doesn’t introduce new company data. Reassessing Ocular Therapeutix
- Neutral Sentiment: Ocular is expected to report quarterly earnings on Monday; the report and management commentary could swing sentiment short term depending on revenue/expense trajectory and product performance. Earnings Expected
- Neutral Sentiment: An insider (Nadia Waheed) sold 3,510 shares at $7.74 (a ~1.1% reduction in her holdings) — a small sale relative to existing ownership and unlikely by itself to change investor conviction. SEC Filing - Waheed Form 4
- Negative Sentiment: Needham & Company cut its price target on OCUL to $18.00 — a downward adjustment from a sell‑side firm that could weigh on sentiment among growth/biotech investors. Needham Lowers Price Target
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its stake in Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,242 shares during the period. Hilton Head Capital Partners LLC bought a new position in Ocular Therapeutix during the fourth quarter worth about $42,000. Nisa Investment Advisors LLC increased its stake in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 1,392 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix during the 4th quarter valued at $61,000. Finally, State of Wyoming purchased a new position in shares of Ocular Therapeutix in the fourth quarter valued at $78,000. Institutional investors own 59.21% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on OCUL. HC Wainwright lifted their price target on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, December 8th. Citigroup restated an "outperform" rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. TD Cowen reiterated a "buy" rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. Needham & Company LLC cut their price target on shares of Ocular Therapeutix from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Friday, February 20th. Finally, Jefferies Financial Group restated a "buy" rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.78.
Get Our Latest Stock Report on OCUL
Ocular Therapeutix Company Profile
(
Get Free Report)
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
